A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.

Trial Profile

A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma; Astellas Pharma US
  • Most Recent Events

    • 08 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008.
    • 24 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top